Cargando…

Allergen-Immuntherapie: Facts und FAQs

Allergen immunotherapy (AIT) is—when allergen avoidance is not sufficient—the only causative therapy of IgE-mediated allergies against aeroallergenes and Hymenoptera venoms. Allergens can be administered by either subcutaneous injection (SCIT) or sublingual application (SLIT); furthermore, oral immu...

Descripción completa

Detalles Bibliográficos
Autores principales: Mortasawi, V., Pfützner, W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369327/
https://www.ncbi.nlm.nih.gov/pubmed/34402919
http://dx.doi.org/10.1007/s00105-021-04872-8
_version_ 1783739270165430272
author Mortasawi, V.
Pfützner, W.
author_facet Mortasawi, V.
Pfützner, W.
author_sort Mortasawi, V.
collection PubMed
description Allergen immunotherapy (AIT) is—when allergen avoidance is not sufficient—the only causative therapy of IgE-mediated allergies against aeroallergenes and Hymenoptera venoms. Allergens can be administered by either subcutaneous injection (SCIT) or sublingual application (SLIT); furthermore, oral immunotherapy in food allergy was also recently approved. Besides correct indication (positive history and diagnostics of IgE-mediated allergy, insufficient allergen avoidance) particular attention has to be payed to potential contraindications and risks. Furthermore, unwanted side effects, which may be life-threatening, can occur. In the following, frequently asked questions (FAQs) and facts in regard to the decision-making process for the implementation as well as the risk management of AIT are discussed.
format Online
Article
Text
id pubmed-8369327
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-83693272021-08-17 Allergen-Immuntherapie: Facts und FAQs Mortasawi, V. Pfützner, W. Hautarzt Leitthema Allergen immunotherapy (AIT) is—when allergen avoidance is not sufficient—the only causative therapy of IgE-mediated allergies against aeroallergenes and Hymenoptera venoms. Allergens can be administered by either subcutaneous injection (SCIT) or sublingual application (SLIT); furthermore, oral immunotherapy in food allergy was also recently approved. Besides correct indication (positive history and diagnostics of IgE-mediated allergy, insufficient allergen avoidance) particular attention has to be payed to potential contraindications and risks. Furthermore, unwanted side effects, which may be life-threatening, can occur. In the following, frequently asked questions (FAQs) and facts in regard to the decision-making process for the implementation as well as the risk management of AIT are discussed. Springer Medizin 2021-08-17 2021 /pmc/articles/PMC8369327/ /pubmed/34402919 http://dx.doi.org/10.1007/s00105-021-04872-8 Text en © Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Leitthema
Mortasawi, V.
Pfützner, W.
Allergen-Immuntherapie: Facts und FAQs
title Allergen-Immuntherapie: Facts und FAQs
title_full Allergen-Immuntherapie: Facts und FAQs
title_fullStr Allergen-Immuntherapie: Facts und FAQs
title_full_unstemmed Allergen-Immuntherapie: Facts und FAQs
title_short Allergen-Immuntherapie: Facts und FAQs
title_sort allergen-immuntherapie: facts und faqs
topic Leitthema
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8369327/
https://www.ncbi.nlm.nih.gov/pubmed/34402919
http://dx.doi.org/10.1007/s00105-021-04872-8
work_keys_str_mv AT mortasawiv allergenimmuntherapiefactsundfaqs
AT pfutznerw allergenimmuntherapiefactsundfaqs